Literature DB >> 27817812

Neurocognitive impairment is correlated with oxidative stress in patients with moderate-to-severe obstructive sleep apnea hypopnea syndrome.

Yanyu He1, Rui Chen2, Jing Wang1, Wenying Pan1, Yanqiu Sun1, Fei Han3, Qiaojun Wang3, Chunfeng Liu4.   

Abstract

BACKGROUND AND OBJECTIVES: Patients with obstructive sleep apnea hypopnea syndrome (OSAHS) are associated with increased risk of neurocognitive impairment, which are largely recognized as mild cognitive impairment (MCI), and oxidative stress is postulated as one of the underlying mechanisms. This study aimed to investigate the relationship between MCI and oxidative stress biomarkers in OSAHS.
METHODS: A total of 119 middle-aged patients with moderate-to-severe OSAHS were included. Based on the baseline Montreal Cognitive Assessment (MoCA, validated Chinese version), 86 and 33 patients presented with normal cognitive function (NC, MoCA ≥26) and mild cognitive impairment (MCI, MoCA <26), respectively. Overnight PSG, MoCA and serum levels of ischemia-modified albumin (IMA), malondialdehyde (MDA) and advanced oxidation protein products (AOPP) were collected and analyzed.
RESULTS: Compared to NC group, patients with MCI were characterized with significantly greater waist-to-height ratio, AHI, ODI and time ratio of SpO2<90%, and lower average SpO2 and time ratio of rapid eye movement (REM). All three oxidative stress biomarkers were markedly elevated in MCI group. Binary logistic regression analysis demonstrated that MCI is significantly correlated with serum levels of IMA, REM ratio and the age of patients.
CONCLUSIONS: The neurocognitive impairment in moderate-to-severe OSAHS patients is associated with significantly elevated oxidative stress. IMA might be a new useful biomarker correlated with mild cognitive impairment of the patients.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Cognitive impairment; Ischemia-modified albumin; Obstructive sleep apnea hypopnea syndrome; Oxidative stress; Polysomnography

Mesh:

Substances:

Year:  2016        PMID: 27817812     DOI: 10.1016/j.rmed.2016.09.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Obstructive sleep apnea and the effect of CPAP treatment on ischemia-modified albumin levels: a multi effect size meta-analysis with diagnostic test accuracy.

Authors:  Seshadri Reddy Varikasuvu; Naveen Dutt; Dibakar Sahu
Journal:  Sleep Breath       Date:  2018-06-14       Impact factor: 2.816

2.  Use of positive airway pressure in mild cognitive impairment to delay progression to dementia.

Authors:  Virginia Skiba; Marina Novikova; Aarushi Suneja; Beth McLellan; Lonni Schultz
Journal:  J Clin Sleep Med       Date:  2020-06-15       Impact factor: 4.062

3.  Assessment of the cognitive function in adult Egyptian patients with obstructive sleep apnea using the Montreal Cognitive Assessment: a retrospective large-scale study.

Authors:  Jaidaa F Mekky; Shimaa Yousof; Inas Elsayed; Rofida Elsemelawy; Hassan Mahmoud; Heba Elweshahi
Journal:  J Clin Sleep Med       Date:  2022-03-01       Impact factor: 4.062

Review 4.  Biomarkers of dementia in obstructive sleep apnea.

Authors:  Andrée-Ann Baril; Julie Carrier; Alexandre Lafrenière; Simon Warby; Judes Poirier; Ricardo S Osorio; Najib Ayas; Marie-Pierre Dubé; Dominique Petit; Nadia Gosselin
Journal:  Sleep Med Rev       Date:  2018-08-13       Impact factor: 11.609

Review 5.  Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding.

Authors:  James P C Coverdale; Kondwani G H Katundu; Amélie I S Sobczak; Swati Arya; Claudia A Blindauer; Alan J Stewart
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2018-07-20       Impact factor: 4.006

6.  Brain functional changes in tibetan with obstructive sleep apnea hypopnea syndrome: A resting state fMRI study.

Authors:  Dongjie Kang; Zongyuan Qin; Wen Wang; Yun Zheng; Huiying Hu; Yuanyuan Bao; Haihua Bao
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.